Sequenom, Inc.  

(Public, NASDAQ:SQNM)   Watch this stock  
Find more results for sqnm
-0.01 (-0.21%)
After Hours: 2.38 0.00 (0.00%)
Aug 24, 4:32PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.38 - 2.39
52 week 0.82 - 2.53
Open 2.38
Vol / Avg. 1.57M/3.06M
Mkt cap 288.01M
P/E     -
Div/yield     -
EPS -0.35
Shares 119.24M
Beta 1.23
Inst. own 49%
Nov 2, 2016
Q3 2016 Sequenom Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Aug 3, 2016
Q2 2016 Sequenom Inc Earnings Release
Jun 15, 2016
Sequenom Inc Annual Shareholders Meeting
Jun 10, 2016
Sequenom Inc at Jefferies Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -21.54% -12.73%
Operating margin -15.21% -6.14%
EBITD margin - -14.68%
Return on average assets -25.05% -11.76%
Return on average equity - -
Employees 434 -
CDP Score - -


3595 John Hopkins Ct
SAN DIEGO, CA 92121-1121
United States - Map
+1-858-2029000 (Phone)
+1-858-2029001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Sequenom, Inc. is a life sciences company. The Company serves patients and physicians by providing early patient management information. The Company operates through Sequenom Laboratories segment. It conducts its business as a molecular diagnostics clinical laboratory located in San Diego, California and Raleigh-Durham, North Carolina. Its testing focus is on prenatal health that includes molecular-based laboratory developed tests (LDTs). The Company's diagnostic services are provided through its subsidiary, Sequenom Center for Molecular Medicine LLC (SCMM), doing business as Sequenom Laboratories. Sequenom Laboratories develops and validates its tests to be used as a testing service to physicians. Sequenom Laboratories is focused on developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories' test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF test, SensiGene RhD test, VisibiliT test and Test Send-out Agreements.

Officers and directors

Kenneth F. Buechler Ph.D. Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Dirk van den Boom Ph.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Carolyn D. Beaver CPA Chief Financial Officer, Senior Vice President
Age: 57
Bio & Compensation  - Reuters
Jeffrey D. Linton J.D. Senior Vice President, General Counsel, Secretary
Age: 51
Bio & Compensation  - Reuters
Daniel S. Grosu Senior Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
Robin G Weiner Senior Vice President, Corporate Governance and Regulatory Affairs
Age: 59
Bio & Compensation  - Reuters
Richard Alan Lerner M.D. Lead Independent Director
Age: 77
Bio & Compensation  - Reuters
Myla P. Lai-Goldman M.D. Director
Age: 57
Bio & Compensation  - Reuters
Ronald M. Lindsay Ph.D. Director
Age: 67
Bio & Compensation  - Reuters
Catherine J Mackey Director
Age: 60
Bio & Compensation  - Reuters